OncLive TV

OncLive® TV is an editorial video program featuring one-on-one live and/or virtual interviews with key opinion leaders in the oncology field for their expert insight on breaking news, regulatory updates, practice-changing data presented at medical meetings, and other pivotal topics in a cancer specialty, including breast cancer, lung cancer, genitourinary cancers, gastrointestinal cancers, gynecologic cancers, and hematologic cancers.

Dr. Puertas‐Martinez on Carfilzomib and Dexamethasone plus Cyclophosphamide in Multiple Myeloma

August 27th 2022

Borja Puertas‐Martinez, MD, discusses the use of carfilzomib and dexamethasone with or without cyclophosphamide in patients with relapsed/refractory multiple myeloma.

Dr. Sklavenitis-Pistofidis on Single-Cell Dissection of Immune Cells in Smoldering Myeloma

August 26th 2022

Romanos Sklavenitis-Pistofidis, MD, discusses single-cell dissection of bone marrow and peripheral blood immune cells in smoldering multiple myeloma.

Dr. D'Agostino on Factors for Unsustained MRD Negativity in Multiple Myeloma

August 26th 2022

Mattia D'Agostino, MD, discusses factors that could lead to unsustained minimal residual disease negativity in patients with newly diagnosed multiple myeloma who are transplant eligible.

Dr. Gadgeel on CNS Activity Achieved With Adagrasib in KRAS G12C+ NSCLC

August 25th 2022

Shirish M. Gadgeel, MD, discusses the efficacy of adagrasib in patients with KRAS G12C–mutated non–small cell lung cancer and central nervous system metastases.

Dr. Lunning on the Evolution of BTK Inhibitors in CLL

August 24th 2022

Matthew A. Lunning, DO, FACP, discusses the evolution of BTK inhibitors in chronic lymphocytic leukemia.

Dr. Ross on the Role of the Microbiome in CRC

August 24th 2022

Howard M. Ross, MD, discusses the role of the microbiome colorectal cancer.

Dr. Desai on the Ideal Patient for Bladder Preservation in Urothelial Cancer

August 24th 2022

Neil Desai, MD, discusses the ideal patient for bladder preservation in urothelial cancer.

Dr. Jonasch on the Target Population for Treatement with Belzutifan in RCC

August 24th 2022

Eric Jonasch, MD, discusses the best patient population when treating with belzutifan in clear cell renal cell carcinoma.

Dr. Desai on the Evolving Standard of Care in Urothelial Cancer

August 24th 2022

Neil Desai, MD, discusses the evolving standard of care in urothelial cancer.

Dr. Kozuch on the Role of ctDNA Following Surgery in CRC

August 24th 2022

Peter Kozuch, MD, discusses the role of circulating tumor DNA in colorectal cancer.

Dr. O’Shaughnessy on Pembrolizumab in Triple-Negative Breast Cancer

August 23rd 2022

Joyce A. O’Shaughnessy, MD, discusses the sequencing of pembrolizumab with chemotherapy in patients with early-stage triple-negative breast cancer.

Women in Oncology: Resilience That Leads to Innovation

August 23rd 2022

Selina M. Luger, MD, FRCPC; Gail J. Roboz, MD; and Wendy Stock, MD, discuss how they turned their leukemia career “lemons” into “lemonade.”

Dr. Beckermann on the Evolving Adjuvant Setting in RCC

August 22nd 2022

Kathryn E. Beckermann, MD, PhD, discusses the evolving adjuvant treatment setting for renal cell carcinoma.

Dr. Mato on Factors for Choosing BTK Inhibitors or Venetoclax in CLL

August 22nd 2022

Anthony Mato, MD, MSCE, discusses the factors used to make treatment decisions between BTK inhibitors and venetoclax in chronic lymphocytic leukemia.

Dr. Garcia on the Role of Ruxolitinib in Myelofibrosis

August 22nd 2022

Jacqueline S. Garcia, MD, discusses the role of ruxolitinib (Jakafi) in myelofibrosis.

Dr. Levy on the Approval of Trastuzumab Deruxtecan in HER2-Mutant NSCLC

August 19th 2022

Benjamin Levy, MD, discusses the significance of the FDA approval of fam-trastuzumab deruxtecan-nxki in HER2-mutant non–small cell lung cancer.

Dr. Choueiri on the Future Examination of Adjuvant Pembrolizumab in RCC

August 19th 2022

Toni Choueiri, MD, discusses the future examination of adjuvant pembrolizumab in renal cell carcinoma.

Dr. Nassif on Examining Gut Microbial Signatures in the Tumor Microenvironment

August 19th 2022

Elise Nassif, MD, discusses examining gut microbial signatures in the tumor microenvironment.

Dr. Long on Evaluating Adjuvant Pembrolizumab vs Placebo in Melanoma

August 19th 2022

Georgina V. Long, BSc, PhD, MBBS, FRACP, discusses evaluating pembrolizumab vs placebo in stage IIB or IIC melanoma.

Women in Oncology: Bringing Advances From the Lab Into the Clinic

August 19th 2022

Selina M. Luger, MD, FRCPC; Gail J. Roboz, MD; and Wendy Stock, MD, discuss what motivated them to continue working toward improvements in the leukemia field, even when outcomes were dismal and treatment options were scarce.